In September, PerkinElmer announced its intent to acquire Caliper for $10.50 per share, for a total net purchase price of approximately $600 million in cash.

PerkinElmer chairman and CEO Robert Friel said the acquisition will enhance their ability to provide customers with the complementary technologies, services and knowledge they need to drive innovation from in vivo to in vitro imaging, and provide expanded offerings across their biomedical, diagnostics, environmental and food safety end-markets.

"He is also very pleased to welcome Caliper’s CEO Kevin Hrusovsky to PerkinElmer," Friel said.

Caliper CEO Kevin Hrusovsky said they are very excited about the opportunities ahead of them following the combination of two highly successful businesses.